Policy & Regulation
Genmab reports 28.2-month median overall survival with petosemtamab combination in Phase 2 trial
26 October 2026 - Danish biotechnology company Genmab A/S (CPH:GMAB) on Monday reported updated Phase 2 results showing median overall survival of 28.2 months with investigational petosemtamab plus pe...
Akeso presents Phase III HARMONi-GI1 trial results in biliary tract cancer at ESMO 2026
26 October 2026 - Chinese biopharmaceutical company Akeso Inc (HKEX:9926) announced on Sunday the presentation of results from the randomised, controlled, double-blind, multicentre, registrational Pha...
Sichuan Kelun-Biotech announces Phase III OptiTROP-Lung04 study results at 2026 ESMO
26 October 2026 - Chinese biopharmaceutical company Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (Kelun-Biotech) (HKG:6990) announced on Sunday the presentation at the 2026 European Society for Medi...
Zhejiang Wenda Pharma reports positive NHWD-870 HCl oral BET inhibitor Phase II trial results at 2026 ESMO Annual Meeting
26 October 2026 - China-based Zhejiang Wenda Pharmaceutical Technology Co Ltd announced on Sunday the publication of its phase II clinical trial data for NHWD-870 HCl, an oral BET inhibitor, in Chines...
Lunit and Summit to apply AI-powered SCOPE IO platform for tumour microenvironment analysis in immuno-oncology development
26 October 2026 - South Korea-based Lunit Inc (KRX:328130), a provider of AI solutions for cancer diagnostics and therapeutics, and US biopharmaceutical oncology company Summit Therapeutics Inc (NASDA...
Galderma secures Chinese approval for Relfydess to treat frown lines
23 October 2026 - Dermatology company Galderma (SIX:GALD) said on Friday that it has received approval from China's National Medical Products Administration for Relfydess (relabotulinumtoxinA) to...